Business

India’s Pharma Market Grows 8.4% In FY25; Boosted By Chronic Therapies & New Drug Launches

India’s pharma market grew by 8.4% during the financial year 2024-25, propelled by strong performance in key chronic therapy areas, according to market research firm Pharmarack.

The cardiac segment led with a 10.8% value growth, followed closely by gastrointestinal (10.2%) and anti-diabetic (8%) therapies.

Together, these three therapy areas contributed 34% of the total pharma market sales, helping push the industry’s overall turnover to over ₹2.25 trillion.

Top-Selling Drugs Led By Chronic Treatments

Despite the chronic therapies dominating in growth, GSK’s antibiotic Augmentin emerged as the top-selling drug of FY25 with ₹816 crore in sales.

USV’s Glycomet GP, an anti-diabetic medication, followed closely with ₹803 crore in sales.

While value growth was strong, unit sales in the domestic market recorded a modest 1.2% increase, indicating that growth was largely price-driven.

Empagliflozin Patent Expiry Sparks Price War

March 2025 saw a significant market shift with the diabetes molecule empagliflozin going off-patent.

Within a month, 86 brands from 19 companies launched empagliflozin-based products. Sheetal Sapale, vice-president (commercial) at Pharmarack, noted a steep price drop—around 85%—with prices falling from ₹60-70 per tablet to just ₹5-15.

Despite a rise in volume, the value declined due to this price erosion.

Anti-Obesity Market Gets Boost From Mounjaro

The launch of Eli Lilly’s Mounjaro (tirzepatide) in March 2025 added momentum to India’s emerging anti-obesity market.

In just one month, Mounjaro contributed ₹1.4 crore to the segment’s ₹576 crore moving annual turnover. Semaglutide, another GLP-1-based drug, accounted for 69% of this total over the previous 12 months.

Double-Digit Growth For Leading Companies

Several leading pharma companies posted strong domestic value growth in March 2025. Sun Pharma (14.9%), Torrent Pharma (14.7%), Intas (12.8%), and Zydus (10.8%) all recorded double-digit growth.

Overall, the pharma market witnessed a 7.5% value growth and 1.8% unit growth in March alone, reflecting broad-based strength across segments.

Also Read: India’s $2.7 Billion PLI Scheme Set To Boost Local Electronics Manufacturing

Purnima Mishra

Recent Posts

Badrinath Temple To Close For Winter Season; Char Dham Yatra Ends

Shri Badrinath Dham in Uttarakhand will close Monday for winter, marking the conclusion of the…

50 mins ago

PM Modi Extends Greetings On Chhath Puja; Seeks Chhathi Maiya’s Blessings For Devotees

PM Modi extended greetings on the final day of Chhath Puja, describing the festival as…

1 hour ago

Chhath Puja Concludes With Usha Arghya As Devotees Offer Prayers To Rising Sun

The four-day Chhath Puja festival will conclude on Monday with Usha Arghya, the final offering…

2 hours ago

Prince William, Princess Catherine To Arrive In Mumbai For Earthshot Prize

Britain's Prince William and Princess Catherine will arrive in Mumbai on Monday for the 2026…

2 hours ago

PM Modi To Attend ASEAN-India & East Asia Summits In Philippines

Prime Minister Narendra Modi is set to visit Manila to participate in the 23rd ASEAN-India…

3 hours ago

Prince William And Catherine To Visit Mumbai For Earthshot Prize 2026

Prince William and Catherine will visit Mumbai from November 16 to 18 for the Earthshot…

10 hours ago